24th Feb 2005 13:00
Pfizer to Acquire Idun Pharmaceuticals New technology platform has potential applications in liver disease, inflammation and cancer NEW YORK and SAN DIEGO, Feb. 24 -- Pfizer Inc today announced that it has entered into an agreement to acquire Idun Pharmaceuticals Inc., a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases. Financial terms of the agreement were not disclosed. Idun has built a leading intellectual property position in apoptosis. The company has an extensive patent portfolio consisting of more than 150 issued patents covering drug targets, new chemical entities (NCEs), drug-screening assays, diagnostics and antibodies. Idun's technology is focused on the control of caspase activity. Caspases are a group of cellular proteases involved in the pathway of apoptosis and inflammation. Idun has developed therapeutic applications focused on inhibiting caspase activity as potential treatments for liver disease and inflammation. Idun also has programs targeting the activation of caspases as potential treatments for cancer. "The acquisition of Idun is a further step in our strategy to augment Pfizer's internal research and development efforts with high-potential, externally sourced product candidates and technologies," said Martin Mackay, Senior Vice President Worldwide Research & Technology for Pfizer Inc. "Idun has built a leading technology platform in controlling caspase activity and we see potential broad application of this technology in treating liver damage associated with viral and non-viral diseases plus other areas of significant unmet medical need." "Pfizer's acquisition of Idun is an important milestone for the company. Pfizer is an ideal fit to advance Idun's promising pipeline through the critical stages of development and commercialization and provides a platform to exploit Idun's technology across various potential applications," said Steven J. Mento, President and CEO of Idun. Idun's lead compound, IDN-6556, a first-in-class pan caspase inhibitor, is in Phase II clinical trials in liver transplantation and in patients infected with Hepatitis C virus. Recently reported data from a Phase IIA study show that IDN-6556 given orally was well-tolerated and significantly improved markers of liver damage in patients infected with the Hepatitis C virus (HCV), an infection that affects up to 170 million patients worldwide. IDN-6556 may represent a new class of drugs that protect the liver from inflammation and cellular damage induced by viral infections and other causes. In addition to IDN-6556, Idun has a robust preclinical pipeline including a number of programs in inflammation and oncology. Based in San Diego, Idun is a private company co-founded by Robert Horvitz, Ph.D., Professor of Biology at MIT, and John Reed, M.D., Ph.D., CEO of the Burnham Institute. Dr Horvitz was awarded the Nobel Prize for Medicine in 2002 for his discoveries concerning the regulation of organ development and apoptosis. The acquisition is expected to close during the second quarter of the year. DISCLOSURE NOTICE: The information contained in this release is as of February 24, 2005. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about the research and development program of a company that Pfizer has agreed to acquire and the potential efficacy of product candidates that might result from the program that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development activities; decisions by regulatory authorities regarding whether and when to approve any drug applications that may result from the program as well as their decisions regarding labeling and other matters that could affect the commercial potential of product candidates that may result from the program; and competitive developments. A further list and description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2003 and in its reports on Form 10-Q and Form 8-K. SOURCE Pfizer Inc 02/24/2005 /CONTACT: Steven J Mento, Ph.D., of Idun, +1-858-646-8105, [email protected]; Stephen Lederer of Pfizer Inc, +1-860-732-9783, [email protected] / /Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html/ /Photo: A free corporate logo to accompany this story is available immediately via Wieck Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call 972-392-0888./ /Company News On-Call: http://www.prnewswire.com/comp/688250.html / /Web site: http://www.pfizer.com / (PFE) ENDRelated Shares:
PFZ.L